Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Vanda Pharmaceuticals announced the U.S. commercial availability of NEREUS (tradipitant), the first new prescription medicine for motion sickness in over 40 years. The drug targets a large patient population of 65 to 78 million Americans and is available through a direct-to-consumer portal at a cash-pay price of $85 per dose.
Key figures
- Drug Name
- NEREUS™ (tradipitant)
- Cash pay price
- $85 per dose
- Patients affected
- 65 to 78 million Americans
- Standard list price
- $255 per dose
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.